Global Pharmaceutical Markets

Table of Contents

• Global Pharmaceutical Markets

Chapter- 1: SUMMARY

• AGING POPULATIONS AND CHRONIC DISEASES
• OVERALL GLOBAL PHARMACEUTICAL MARKETS
• SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, THROUGH 2013 ($ BILLIONS)
• SUMMARY FIGURE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, 2006-2013 ($ BILLIONS)

Chapter- 2: OVERVIEW

• BACKGROUND ON THE INDUSTRY
• RECENT HISTORY
• BENEFITS, PROBLEMS, AND REGULATION
• CHANGES IN THE INDUSTRY
• HEALTHCARE EXPENDITURES
  • TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS REPORT, 2000 AND 2005 (% OF GDP)

Chapter- 3: THE PHARMACEUTICAL INDUSTRY

• TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007 ($ BILLIONS)
• RESEARCH AND DEVELOPMENT EXPENDITURES
  • TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY R&D SPENDING, 2006 AND 2007 ($ BILLIONS)
• SECTOR PERFORMANCE
• BRANDED PHARMACEUTICALS
  • TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
  • TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
  • TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)
  • TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)

Chapter- 4: UNITED STATES

• INTRODUCTION
  • TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)
  • FIGURE 1 U.S. POPULATION, 1998-2013 (MILLIONS)
  • TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)
• THE U.S. HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURES IN THE U.S.
  • FIGURE 2 U.S. HEALTHCARE EXPENDITURES, 1980-2006 ($ BILLIONS)
  • TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006
  • TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004 ($ BILLIONS, %)
  • TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006 ($ BILLIONS)
• COMMON HEALTH PROBLEMS IN THE U.S.
  • TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE
  • TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)
• SMOKING
• CANCER
  • TABLE 16 INVASIVE CANCER, U.S., 2004 (%)
  • TABLE 16 (CONTINUED)
  • TABLE 17 CANCER DEATHS, U.S., 2004 (%)
  • TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW CASES)
• HIV INFECTION
• GOVERNMENT REGULATIONS
• INTRODUCTION
• DRUG DISCOVERY
• Preclinical Testing and Submission of an IND
• CLINICAL TRIALS
• TIMELINE AND COSTS
• SUBMISSION OF AN NDA OR BLA
• POST-FDA APPROVAL
• NEW DRUG APPROVALS
  • FIGURE 3 NME APPROVALS, 1997-2007
  • FIGURE 4 NME APPROVALS IN TWO SEVEN-YEAR PERIODS, 1994-2007
  • TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA, 1980 TO MARCH 20, 2007
• DO CURRENT CORPORATE MANAGEMENT PRACTICES HAVE A ROLE IN R&D SHORTFALLS?
• BLOCKBUSTER DRUGS
  • TABLE 20 NME APPROVALS BY DISORDER, 2004-MARCH 20, 2008
• OTHER SUCCESSFUL THERAPEUTIC AGENTS
  • TABLE 21 BOTOX SALES, 1993-2012 ($ MILLIONS)
• IS THE NIH FUNDING CRISIS CONTRIBUTING TO SHORTFALLS IN DRUG DISCOVERY?
• PHARMACEUTICAL PRICING
• FACTORS AFFECTING DRUG PRICES
• PHARMACY BENEFIT MANAGERS (PBMS)
  • TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007 (%)
• Pharmacy Benefit Managers … (Continued)
• PHARMACEUTICAL FLOW FROM MANUFACTURER TO PATIENT
• PHARMACEUTICAL WHOLESALING
  • TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (%, $ BILLIONS)
• PHARMACEUTICAL RETAILING
  • TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND 2007 (RX MILLIONS)
• EXPORT-IMPORT PROFILE
  • TABLE 25 EXPORT-IMPORT PROFILE, U.S., 1995-2006 ($ BILLIONS)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
  • TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.S.
  • TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)
• IMPORTANT ORGANIZATIONS IN THE U.S.
• PHRMA, THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
• GPHA, GENERIC PHARMACEUTICAL ASSOCIATION
• CHPA (CONSUMER HEALTHCARE PRODUCTS ASSOCIATION)
• COMPANY PROFILES: UNITED STATES
• ABBOTT LABORATORIES
• BIOGEN IDEC
• AMGEN
• BRISTOL-MYERS SQUIBB
• FOREST LABORATORIES
• GENENTECH
• GENZYME
• JOHNSON & JOHNSON
• ELI LILLY AND COMPANY
• MERCK & CO. INC.
• PFIZER
• WYETH PHARMACEUTICALS
• TEVA PHARMACEUTICALS
• Teva North America

Chapter- 5: CANADA

• INTRODUCTION
  • TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013 (MILLIONS)
  • FIGURE 5 CANADA: POPULATION 1998-2013 (MILLIONS)
  • TABLE 32 DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013 (MILLIONS)
• THE CANADIAN HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN CANADA
  • TABLE 33 HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005
• COMMON HEALTH PROBLEMS IN CANADA
• ALZHEIMER' S DISEASE AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE AND CANCER
• HIV INFECTION
• PHARMACEUTICAL PRICING
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 34 BRANDED PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 35 GENERIC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER (OTC) MEDICATIONS IN CANADA
  • TABLE 36 OTC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)
  • TABLE 37 TOP SELLING CATEGORIES OF OTC MEDICATIONS IN CANADA (%)
• IMPORTANT ORGANIZATIONS IN CANADA
• STATISTICS CANADA
• RX&D, CANADA' S RESEARCH-BASED PHARMACEUTICAL COMPANIES
• CGPA (CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION)
• NDMAC (THE NONPRESCRIPTION DRUG MANUFACTURERS ASSOCIATION OF CANADA)
• COMPANY PROFILES: CANADA
• ABBOTT LABORATORIES, LIMITED
• ACTELION
• ASTRAZENECA CANADA INC.
• BAYER, INC.
• BRISTOL-MYERS SQUIBB CANADA
• ELI LILLY CANADA INC.
• GLAXOSMITHKLINE INC.
• HOFFMANN-LA ROCHE LIMITED
• LUNDBECK CANADA INC.
• MERCK FROSST CANADA LTD.
• NOVARTIS PHARMACEUTICALS CANADA INC.
• PFIZER CANADA INC.
• PURDUE PHARMA (1956)
• SANOFI-AVENTIS CANADA
• SOLVAY PHARMA INC
• WYETH PHARMACEUTICALS
• Wyeth Pharmaceuticals (continued)

Chapter- 6: MEXICO

• INTRODUCTION
  • TABLE 38 OVERALL PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 39 POPULATION TRENDS, MEXICO, THROUGH 2013 (MILLIONS)
• THE MEXICAN HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN MEXICO
  • TABLE 40 HEALTHCARE EXPENDITURE: MEXICO, 2000-2005
• COMMON HEALTH PROBLEMS IN MEXICO
• OBESITY AND RELATED CONDITIONS
• DIABETES: THE LEADING CAUSE OF DEATH
• HIV INFECTION
• PHARMACEUTICAL REGULATION AND PRICING
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 41 BRANDED PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 42 GENERIC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER (OTC) MEDICATIONS IN MEXICO
  • TABLE 43 OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)
• IMPORTANT ORGANIZATIONS IN MEXICO
• STATISTICS MEXICO: SISTEMAS NACIONALES ESTADÍSTICO Y DE INFORMACIÓN GEOGRÁFICA (SNEIG)
• AFAMELA (ASOCIACION DE FABRICANTES DE MEDICAMENTOS DE LIBRE ACCESO AC)
• AMIIF (ASOCIACIÓN MEXICANA DE INDUSTRIALES DE INVESTIGACIÓN FARMACÉUTIA A.C., MEXICAN ASSOCIATION OF PHARMACEUTICAL COMPANIES)
• CANIFARMA (CAMARA NACIONAL DE LA INDUSTRIA FARMACEUTICA)
• FIFARMA, THE LATIN AMERICAN FEDERATION OF THE PHARMACEUTICAL INDUSTRY
• ILAR (INDUSTRIO LATINOAERMICANA DE AUTOMEDICACION RESPONSABLE)

Chapter- 7: BRAZIL

• INTRODUCTION
  • TABLE 44 OVERALL PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 45 POPULATION TRENDS, BRAZIL, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN BRAZIL
• THE HEALTHCARE SYSTEM (MEDICARE)
• PHARMACEUTICAL PRICING
• HEALTH PROBLEMS IN BRAZIL
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 46 BRANDED PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 47 GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 48 OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN BRAZIL
• BRAZILIAN INSTITUTE OF GEOGRAPHY AND STATISTICS

Chapter- 8: EUROPE

• HEALTHCARE IN EUROPE
• REIMBURSEMENT OF PHARMACEUTICALS
• POPULATION DEMOGRAPHICS IN EUROPE
• POPULATION GROWTH, MEDIAN AGE, AND LIFE EXPECTANCY
• EXCESS WEIGHT
• LIFE EXPECTANCY IN EUROPE
• PHARMACEUTICAL MARKETS IN EUROPE
  • TABLE 49 TOP FIVE PHARMACEUTICAL MARKETS, EUROPE, THROUGH 2013 ($ BILLIONS)
• PROPRIETARY PRESCRIPTION MEDICATIONS (ALSO CALLED BRANDED MEDICATIONS AND ETHICAL PHARMACEUTICALS)
  • TABLE 50 BRANDED PRESCRIPTION PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
• DATA EXCLUSIVITY
• GENERIC MEDICATIONS
  • TABLE 51 GENERIC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)
• GENERIC SMALL MOLECULES
• BIOSIMILARS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 52 OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)

Chapter- 9: FRANCE

• INTRODUCTION
  • TABLE 53 OVERALL PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 54 POPULATION TRENDS, FRANCE, THROUGH 2013 (MILLIONS)
  • FIGURE 6 FRANCE: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 55 DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013 (MILLIONS)
• HEALTHCARE EXPENDITURE IN FRANCE
  • TABLE 56 HEALTHCARE EXPENDITURE: FRANCE, 2000-2005
• COMMON HEALTH PROBLEMS IN FRANCE
• ALZHEIMER' S DISEASE AND RELATED DEMENTIAS
  • TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE
  • TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY CLASS, FRANCE, 2006 (%)
• PHARMACEUTICAL PRICING
  • FIGURE 7 VALUE BREAKDOWN OF PHARMACEUTICALS, FRANCE, 2005 (%)
  • FIGURE 7 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
  • FIGURE 8 LEADING GENERIC MANUFACTURERS, MARKET SHARE, FRANCE, 2006 (% SHARE)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER (OTC) MEDICATIONS IN FRANCE
  • TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)
  • TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS IN FRANCE (%)
• EXPORT-IMPORT PROFILE
  • TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 ($ BILLIONS)
  • TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 ($ BILLIONS)
• PHARMACEUTICAL DISTRIBUTION
• WHOLESALERS
  • FIGURE 9 LEADING WHOLESALERS MARKET SHARE, FRANCE, 2006-2007 (% SHARE)
• FRANCE' S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
  • TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (EUROS, MILLIONS)
  • TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (EUROS, MILLIONS)
• IMPORTANT ORGANIZATIONS IN FRANCE
• INSEE (NATIONAL INSTITUTE FOR STATISTICS AND ECONOMIC STUDIES)
• LEEM, THE FRENCH PHARMACEUTICAL COMPANIES ASSOCIATION
• CSRP (SYNDICATE OF PHARMACEUTICAL DISTRIBUTORS:
• FRANCE ALZHEIMER:
• COMPANY PROFILES: FRANCE
• BIOGARAN
• CERP
• MERCK GENERIQUES
• SANDOZ: (SEE GERMANY)
• SANOFI-AVENTIS
• Sanofi-Aventis (Continued)

Chapter- 10: GERMANY

• INTRODUCTION
  • TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013 (MILLIONS)
  • TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013 (MILLIONS)
  • FIGURE 10 GERMANY: POPULATION 1998-2013 (MILLIONS)
• THE GERMAN HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN GERMANY
  • TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005
• COMMON HEALTH PROBLEMS IN GERMANY
• ALZHEIMER' S DISEASE AND RELATED DEMENTIAS
  • TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF PEOPLE)
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE
  • TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY (PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)
• PRICING AND REIMBURSEMENT OF PHARMACEUTICAL AGENTS
  • FIGURE 11 VALUE BREAKDOWN OF PHARMACEUTICALS, GERMANY, 2005 (%)
  • FIGURE 11 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)
  • TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)
• PHARMACEUTICAL DISTRIBUTION
• WHOLESALERS
  • FIGURE 12 LEADING WHOLESALERS MARKET SHARE, GERMANY, 2006-2007 (% SHARE)
• GERMAN PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
  • TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)
  • TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)
• IMPORTANT ORGANIZATIONS IN GERMANY
• DESTATIS (FEDERAL STATISTICAL OFFICE)
• GERMAN FEDERAL MINISTRY FOR EDUCATION AND RESEARCH
• DEUTSCHE DIABETES-UNION
• PHARMA PRIVAT
• BAH, BUNDESVERBAND DER ARZNEIMITTEL-HERSTELLER E.V.
• VFA, THE GERMAN ASSOCIATION OF RESEARCH-BASED PHARMACEUTICAL COMPANIES
• COMPANY PROFILES: GERMANY
• CELESIO AG
• MERCK KGAA
• SANDOZ
• STADA ARZNEIMITTEL AG

Chapter- 11: UNITED KINGDOM (U.K.)

• INTRODUCTION
  • TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)
  • FIGURE 13 U.K. POPULATION, 1998-2013 (MILLIONS)
  • TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)
• THE U.K. HEALTHCARE SYSTEM
• HEALTHCARE EXPENDITURE IN THE U.K.
  • TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005
• COMMON HEALTH PROBLEMS IN THE U.K.
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
  • TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050 (MILLIONS OF PEOPLE)
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
  • TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS BY TOP EIGHT CLASSES, U.K., 2006 (%)
  • TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, U.K., 2006 ($ MILLIONS)
• BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN THE U.K. AND REVENUE BREAKDOWN
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
  • TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004 (% OF TOTAL MARKET)
• GENERIC DRUGS
  • TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.K.
  • TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)
  • TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL MARKET)
• EXPORT-IMPORT PROFILE
  • TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006 ($ BILLIONS)
• PHARMACEUTICAL DISTRIBUTION
• WHOLESALERS
  • TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (% OF TOTAL MARKET)
• U.K.' S PHARMACEUTICAL EXPORTS AND IMPORTS IN POUNDS STERLING
  • TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£ BILLIONS)
• IMPORTANT ORGANIZATIONS IN THE U.K.
• NATIONAL STATISTICS U.K.
• ABPI, THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY
• THE BRITISH ASSOCIATION OF PHARMACEUTICAL WHOLESALERS (BAPW)
• COMPANY PROFILES: U.K.
• AAH PHARMACEUTICALS
• GLAXOSMITHKLINE (GSK)
• MAWDSLEY-BROOKS & CO. LTD.
• PHOENIX HEALTHCARE DISTRIBUTION, LTD.
• UNICHEM
• Unichem (Continued)

Chapter- 12: ITALY

• INTRODUCTION
  • TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)
  • FIGURE 14 ITALY: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013 (MILLIONS)
• THE ITALIAN HEALTHCARE SYSTEM AND GROWTH DRIVERS
  • TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005
• COMMON HEALTH PROBLEMS IN ITALY
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
  • TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)
• BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN ITALY
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN ITALY
  • FIGURE 15 VALUE BREAKDOWN OF PHARMACEUTICALS, ITALY, 2005 (%)
  • FIGURE 15 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)
  • TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL MARKET)
• EXPORT-IMPORT PROFILE
  • TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 ($ BILLIONS, ROUNDED)
  • TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL EXPORTS, 2006 (% OF TOTAL MARKET)
  • TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 ($ BILLIONS)
  • TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL IMPORTS, 2006 (% OF TOTAL MARKET)
• ITALY' S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS
  • TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)
  • TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)
• IMPORTANT ORGANIZATIONS IN ITALY
• NATIONAL INSTITUTE FOR STATISTICS (ISTITUTO NAZIONALE DI STATISTICA)
• FARMINDUSTRIA, THE PHARMACEUTICAL MANUFACTURER' S ASSOCIATION OF ITALY
• ASSOGENERICI, THE ITALIAN NATIONAL ASSOCIATION OF GENERIC PHARMACEUTICALS

Chapter- 13: SPAIN

• INTRODUCTION
  • TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
• DRIVERS OF PHARMACEUTICAL SALES GROWTH
• POPULATION AND DEMOGRAPHICS
  • TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013 (MILLIONS)
  • FIGURE 16 SPAIN: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013 (MILLIONS)
• THE SPANISH HEALTHCARE SYSTEM, PRICING, AND PHARMACEUTICAL GROWTH DRIVERS
• THE HEALTHCARE SYSTEM
  • TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005
• DRUG PRICING POLICIES
• COMMON HEALTH PROBLEMS IN SPAIN
• ALZHEIMER' S DISEASE (AD) AND RELATED DEMENTIAS
• OBESITY AND RELATED CONDITIONS
• DIABETES
• CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)
  • TABLE 113 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, SPAIN, 2006
• GROWTH DRIVERS
• BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN SPAIN
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN SPAIN
  • FIGURE 17 VALUE BREAKDOWN OF PHARMACEUTICALS, SPAIN, 2005 (%)
  • FIGURE 17 (CONTINUED)
• MARKET SECTORS
• BRANDED PRESCRIPTION PHARMACEUTICALS
  • TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
• GENERIC DRUGS
  • TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)
• DRIVERS AND RESTRAINTS
• OVER-THE-COUNTER MEDICATIONS
  • TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ MILLIONS)
• EXPORT-IMPORT PROFILE
  • TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)
  • TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)
• IMPORTANT ORGANIZATIONS IN SPAIN
• NATIONAL STATISTICS INSTITUTE (INSTITUTO NACIONAL DE ESTADISTICA)
• FARMAINDUSTRIA, THE NATIONAL ASSOCIATION OF THE PHARMACEUTICAL INDUSTRY IN SPAIN
• AESEG, THE SPANISH ASSOCIATION OF GENERIC PHARMACEUTICALS MANUFACTURERS
• ANEFP, THE NATIONALS ASSOCIATION OF OVER-THE-COUNTER MEDICATIONS
• CEAFA, CONFEDERACTION ESPANOLA DE FAMILIARES ENFERMOS DE ALZHEIMER' S Y OTRAS DEMENCIAS

Chapter- 14: SMALLER PHARMACEUTICAL MARKETS IN EUROPE

• GREECE
• INTRODUCTION
  • TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013 (MILLIONS)
  • FIGURE 18 GREECE: POPULATION, 1998-2013
• (MILLIONS)
  • TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013 (MILLIONS)
• THE GREEK HEALTHCARE SYSTEM
• Structure of the Healthcare System
• Healthcare Expenditures
  • TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005
• COMMON HEALTH PROBLEMS IN GREECE
• Pharmaceutical Pricing
  • TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS, BY CLASS, GREECE, 2004
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN GREECE
  • FIGURE 19 VALUE BREAKDOWN OF PHARMACEUTICALS, GREECE, 2005 (%)
• Growth Drivers
• Barriers to Pharmaceutical Revenue Growth in Greece
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)
• Drivers and Restraints
• Over-the-Counter Medications
  • TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ MILLIONS)
  • TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN GREECE
• STATISTICS GREECE
• THE HELLENIC ASSOCIATION OF PHARMACEUTICAL COMPANIES (SFEE)
• EFEX, THE GREEK PROPRIETARY ASSOCIATION
• THE NETHERLANDS
• INTRODUCTION
  • TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)
  • FIGURE 20 NETHERLANDS: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)
• THE DUTCH HEALTHCARE SYSTEM
• Structure of the Healthcare System
• Healthcare Expenditures
  • TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-2005
• COMMON HEALTH PROBLEMS IN THE NETHERLANDS
• Drug Pricing
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN THE NETHERLANDS
  • FIGURE 21 VALUE BREAKDOWN OF PHARMACEUTICALS, NETHERLANDS, 2005 (%)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 132 BRANDED PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 133 GENERIC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)
• Drivers and Restraints
• Over-the-Counter Medications
  • TABLE 134 OTC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ MILLIONS)
  • TABLE 135 LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN THE NETHERLANDS
• STATISTICS NETHERLANDS
• NEFARMA, THE ASSOCIATION OF INNOVATE PHARMACEUTICALS IN THE NETHERLANDS
• BOGIN, THE ASSOCIATION OF DUTCH GENERIC MEDICATIONS INDUSTRY
• NEPROPHARM, THE NETHERLANDS ASSOCIATION OF OVER-THE-COUNTER PRODUCTS
• BELGIUM
• INTRODUCTION
  • TABLE 136 OVERALL PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 137 POPULATION TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)
  • FIGURE 22 BELGIUM: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 138 DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)
• THE BELGIAN HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 139 HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005
• COMMON HEALTH PROBLEMS IN BELGIUM
• DRUG PRICING
• REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN BELGIUM
  • FIGURE 23 VALUE BREAKDOWN OF PHARMACEUTICALS, BELGIUM, 2005 (%)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 140 BRANDED PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 141 GENERIC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 142 OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ MILLIONS)
  • TABLE 143 LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN BELGIUM
• STATISTICS BELGIUM
• PHARMA.BE, THE GENERAL ASSOCIATION OF THE MEDICINES INDUSTRY
• EUROGENERICS
• POLAND
• INTRODUCTION
  • TABLE 144 OVERALL PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 145 POPULATION TRENDS, POLAND, THROUGH 2013 (MILLIONS)
  • FIGURE 24 POLAND: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 146 DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013 (MILLIONS)
• COMMON HEALTH PROBLEMS IN POLAND
• THE POLISH HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 147 HEALTHCARE EXPENDITURE: POLAND, 2000-2005
• DRUG PRICING
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 148 BRANDED PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 149 GENERIC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 150 OTC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ MILLIONS)
  • TABLE 151 LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN POLAND
• POLISH CENTRAL STATISTICS OFFICE
• POLFARMED, POLISH CHAMBER OF PHARMACEUTICALS INDUSTRY AND MEDICAL DEVICES
• PASMI, THE POLISH ASSOCIATION OF THE SELF-MEDICATION INDUSTRY
• PORTUGAL
• INTRODUCTION
  • TABLE 152 OVERALL PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 153 POPULATION TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)
  • FIGURE 25 PORTUGAL: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 154 DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)
• THE PORTUGUESE HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 155 HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005
• Pharmaceutical Pricing
  • FIGURE 26 VALUE BREAKDOWN OF PHARMACEUTICALS, PORTUGAL, 2005 (%)
  • FIGURE 26 (CONTINUED)
• COMMON HEALTH PROBLEMS IN PORTUGAL
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 156 BRANDED PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 157 GENERIC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 158 OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ MILLIONS)
  • TABLE 159 LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN PORTUGAL
• STATISTICS PORTUGAL
• APOGEN, PORTUGUESE ASSOCIATION OF GENERIC MEDICATIONS
• APIFARMA, THE ASSOCIATION OF THE PORTUGUESE PHARMACEUTICAL INDUSTRY
• SWITZERLAND
• INTRODUCTION
  • TABLE 160 OVERALL PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 161 POPULATION TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)
  • FIGURE 27 SWITZERLAND: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 162 DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)
• Common Health Problems in Switzerland
• THE SWISS HEALTHCARE SYSTEM
• Structure of the Healthcare System
  • TABLE 163 HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005
• Pharmaceutical Environment and Pricing
• Pharmaceutical Environment …(Continued)
  • FIGURE 28 VALUE BREAKDOWN OF PHARMACEUTICALS, SWITZERLAND, 2005 (%)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 164 BRANDED PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 165 GENERIC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 166 OTC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ MILLIONS)
  • TABLE 167 LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF TOTAL MARKET)
• IMPORTANT ORGANIZATIONS IN SWITZERLAND
• SWISS FEDERAL STATISTICS OFFICE
• COMPANY PROFILES
• NOVARTIS INTERNATIONAL AG
• SWEDEN
• INTRODUCTION
  • TABLE 168 OVERALL PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 169 POPULATION TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)
  • FIGURE 29 SWEDEN: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 170 DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)
• HEALTH PROBLEMS AND HEALTHCARE IN SWEDEN
• The Healthcare System
  • TABLE 171 HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005
• Pharmaceutical Pricing
  • FIGURE 30 VALUE BREAKDOWN OF PHARMACEUTICALS, SWEDEN, 2005 (%)
• Health Problems in Sweden
  • TABLE 172 LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006 (% OF TOTAL MARKET, BY VALUE)
• MARKET SECTORS
• Branded Pharmaceuticals
  • TABLE 173 BRANDED PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 174 GENERIC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 175 OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN SWEDEN
• STATISTICS SWEDEN
• FGL, THE SWEDISH ASSOCIATION FOR GENERIC PHARMACEUTICALS
• AUSTRIA
• INTRODUCTION
  • TABLE 176 OVERALL PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 177 POPULATION TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
  • FIGURE 31 AUSTRIA: POPULATION, 1998-2013 (MILLIONS)
  • TABLE 178 DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN AUSTRIA
• The Healthcare System
• Pharmaceutical Pricing
  • TABLE 179 HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005
• Health Problems in Austria
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 180 BRANDED PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 181 GENERIC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 182 OTC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN AUSTRIA
• STATISTICS AUSTRIA
• PHARMIG, THE
• IGEPHA, THE AUSTRIAN SELF-MEDICATION INDUSTRY
• HUNGARY
• INTRODUCTION
  • TABLE 183 OVERALL PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
• HEALTH PROBLEMS AND HEALTHCARE IN HUNGARY
• The Healthcare System
• Pharmaceutical Pricing
• Health Problems in Hungary
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 184 BRANDED PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 185 GENERIC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 186 OTC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN HUNGARY
• HUNGARIAN CENTRAL STATISTICS OFFICE
• MAGYOSZ, THE HUNGARIAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION
• FINLAND
• INTRODUCTION
  • TABLE 187 OVERALL PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 188 POPULATION TRENDS, FINLAND, THROUGH 2013 (MILLIONS)
  • TABLE 189 DEMOGRAPHIC TRENDS, FINLAND, THROUGH 2013 (MILLIONS)
• HEALTH PROBLEMS AND HEALTHCARE IN FINLAND
• The Healthcare System
• PHARMACEUTICAL PRICING
• Health Problems in Finland
• MARKET SECTORS
  • TABLE 190 LEADING THERAPEUTIC CATEGORIES, FINLAND, 2006 (% OF TOTAL MARKET, BY VALUE)
• Branded Prescription Pharmaceuticals
  • TABLE 191 BRANDED PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 192 GENERIC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 193 OTC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN FINLAND
• STATISTICS FINLAND
• IMPORTANT ORGANIZATIONS IN EUROPE
• THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA)
• THE EUROPEAN GENERICS ASSOCIATION (EGA)
• THE ASSOCIATION OF THE EUROPEAN SELF-MEDICATION INDUSTRY (AESGP)

Chapter- 15: ASIA

• JAPAN
• INTRODUCTION
  • TABLE 194 OVERALL PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 195 POPULATION TRENDS, JAPAN, THROUGH 2013 (MILLIONS)
  • TABLE 196 DEMOGRAPHIC TRENDS, JAPAN, THROUGH 2013 (MILLIONS)
  • FIGURE 32 JAPAN: POPULATION, 1998-2013 (MILLIONS)
• THE JAPANESE HEALTHCARE SYSTEM
• Healthcare Expenditures in Japan
  • TABLE 197 HEALTHCARE EXPENDITURE: JAPAN, 2000-2005
• Common Health Problems in Japan
  • TABLE 198 LEADING CAUSES OF DEATH, JAPAN, 2005
• Cancer
  • TABLE 199 LEADING FORMS OF CANCER, JAPAN, 2005
• Alzheimer' s Disease and Related Dementias
• Obesity and Diabetes
• Cardiovascular Disease
• Smoking
• PHARMACEUTICAL PRICING
• Pharmaceutical Pricing (Continued)
• Pricing of Generic Drugs
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 120 BRANDED PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 201 GENERIC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
• OVER-THE-COUNTER MEDICATIONS IN JAPAN
  • TABLE 202 OTC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)
  • TABLE 203 LEADING OTC CATEGORIES, JAPAN
• IMPORTANT ORGANIZATIONS IN JAPAN
• STATISTICS BUREAU
• MINISTRY OF HEALTH, LABOUR, & WELFARE
• JPMA, JAPAN PHARMACEUTICAL MANUFACTURER' S ASSOCIATION
• JSMI, JAPANESE SELF-MEDICATION INDUSTRY
• COMPANY PROFILES
• ASTELLAS PHARMA
• SAWAI PHARMACEUTICAL COMPANY LTD.
• TAKEDA PHARMACEUTICAL COMPANY LTD.
• CHINA
• INTRODUCTION
  • TABLE 204 OVERALL PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 205 POPULATION TRENDS, CHINA, THROUGH 2013 (MILLIONS)
  • TABLE 206 DEMOGRAPHIC TRENDS, CHINA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN CHINA
• The Healthcare System
• Pharmaceutical Pricing
• Health Problems in China
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 207 PRESCRIPTION PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
• Over-the-Counter Medications
  • TABLE 208 OTC PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN CHINA
• NATIONAL BUREAU OF STATISTICS OF CHINA
• SOUTH KOREA
• INTRODUCTION
  • TABLE 209 OVERALL PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 210 POPULATION TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)
  • TABLE 211 DEMOGRAPHIC TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN SOUTH KOREA
• The Healthcare System
• Pharmaceutical Pricing
• Health Problems in South Korea
  • TABLE 212 LEADING CAUSES OF DEATH, SOUTH KOREA, 2003
• MARKET SECTORS
• Branded and Generic Prescription Pharmaceuticals
  • TABLE 213 PRESCRIPTION PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 214 OTC PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ MILLIONS)
• IMPORTANT ORGANIZATIONS IN SOUTH KOREA
• KOREAN NATIONAL STATISTICAL OFFICE
• AUSTRALIA
• INTRODUCTION
  • TABLE 215 OVERALL PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 216 POPULATION TRENDS, AUSTRALIA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN AUSTRALIA
• The Healthcare System (Medicare)
• Pharmaceutical Pricing
• Health Problems in Australia
  • TABLE 217 LEADING CAUSES OF DEATH, MEN, AUSTRALIA, 2005 (% OF ALL DEATHS)
  • TABLE 218 LEADING CAUSES OF DEATH, WOMEN, AUSTRALIA, 2004 (% OF ALL DEATHS)
  • TABLE 219 COMMON CHRONIC CONDITIONS, AUSTRALIA, 2005 (% OF POPULATION)
• MARKET SECTORS
• Branded Prescription Pharmaceuticals
  • TABLE 220 BRANDED PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
• Generic Drugs
  • TABLE 221 GENERIC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)
• Over-the-Counter Medications
  • TABLE 222 OTC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ MILLIONS)
  • TABLE 223 TOP OTC PURCHASES, AUSTRALIA (% OF THE POPULATION)
• IMPORTANT ORGANIZATIONS IN AUSTRALIA
• AUSTRALIAN BUREAU OF STATISTICS
• DEPARTMENT OF INNOVATION, INDUSTRY, SCIENCE, AND RESEARCH
• MEDICINES AUSTRALIA
• INDIA
• INTRODUCTION
  • TABLE 224 OVERALL PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
• POPULATION AND DEMOGRAPHICS
  • TABLE 225 POPULATION TRENDS, INDIA, THROUGH 2013 (MILLIONS)
• HEALTHCARE AND HEALTH PROBLEMS IN INDIA
• Pharmaceutical Pricing
• HEALTH PROBLEMS IN INDIA
• MARKET SECTORS
• Overview
  • TABLE 226 TOP INDIAN PHARMACEUTICAL COMPANIES BY REVENUES, 2006 ($ MILLIONS)
• Barriers to Growth in India
• Branded Prescription Pharmaceuticals
  • TABLE 227 PRESCRIPTION PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
• Generics
• Over-the-Counter Medications
  • TABLE 228 OTC PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)
• IMPORTANT ORGANIZATIONS IN INDIA
• MINISTRY OF STATISTICS AND PROGRAMME IMPLEMENTATION
• MINISTRY OF HEALTH
• IDMA, THE INDIAN DRUG MANUFACTURERS ASSOCIATION
• OPPI, THE ORGANISATION OF PHARMACEUTICAL PRODUCERS OF INDIA
• COMPANY PROFILES
• RANBAXY LABORATORIES, LTD
• CIPLA LTD.
• DR. REDDY' S LABORATORIES LTD.
• SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE
• PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES NOT COVERED IN DETAIL IN THIS REPORT
• PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES …
• PHARMACEUTICAL MARKETS…(CONTINUED)
• SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE